Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2008

View Archived Issues

Bristol-Myers Squibb presents overview of second quarter

FDA has granted orphan drug designation to Ikaria's inhaled carbon monoxide for DGF

[11C]MePPEP, a novel PET ligand for CB1 shows good uptake and slow washout in human brain

Preclinical activity supports development of antiinfective acne treatment HB-1345

Preclinical positive results for serotonin receptor antagonists in learning and memory processing

Further phase II data on dimebon in Alzheimer's disease presented

New preclinical, phase I data on CTS-21166 made available

Senexis identifies promising beta-amyloid aggregation inhibitor

Novel anticancer agents described in recent patents

FDA allows Medarex's IND application to initiate phase I clinical trial of MDX-1105

Lorus reports positive results from two toxicology studies of LOR-2040 in bladder cancer

Diatos initiates recruitment into phase II clinical trials of DTS-201 in prostate and breast cancer

New agents for anxiety, psychosis, depression, etc. revealed in patent literature

Recent patents report discovery of novel antidiabetic agents

BioAlliance and APR sign European licensing agreement for ondansetron RapidFilm

Hollis-Eden initiates phase I/II clinical trial of Triolex and methotrexate in RA

Clinical Data acquires Adenosine Therapeutics

Novartis completes recruitment into phase III study of salmon calcitonin

Generex is granted approval to initiate trial of Generex Oral-lyn in IGT

Meda submits registration application to the FDA for extra strength azelastine nasal spray

Cancidas approved for use in pediatric patients

Heplisav phase III study meets primary endpoint

Intercell completes acquisition of Iomai

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...